UNSPSC 51343501: Adefovir

This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H12N5O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6GQP90I798, chemically known as phosphonic acid, ((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)- but generally known as adefovir, which bears US NIH Compound Identifier 60172. Adefovir most often comes in dipivoxil and pivoxil forms. European Medicines Agency schedules Adefovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05264MIG.

UNSPSC 51343501 Adefovir, a Commodity code, does not align with the state and local procurement activity posted under this classification. The code nominates a specific antiviral pharmaceutical product (adefovir), yet the four recent opportunities tagged to it solicited naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription fulfillment capacity (Texas Health and Human Services Commission), medical and first aid supplies for fire rescue operations (City of Tampa), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these procurements target adefovir specifically. The recent solicitation activity reflects state and local demand for emergency medical supplies, pharmaceutical distribution infrastructure, and generic drug supply agreements rather than a discrete antiviral product. Issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and multi-state cooperative purchasing alliances.

The geographic spread spans Florida, Texas, Minnesota, and Oregon through the MMCAP cooperative vehicle. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 annual units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a two-year term with one-year renewal option; the City of Tampa's sealed-bid solicitation 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000 with a one-year award term and two optional one-year renewals, designated as sheltered for certified Small Local Business Enterprises; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers with contract terms effective July 1, 2026. The code shows no clear recent activity aligned with adefovir procurement.